shutterstock_1569359980_sundry-photography

shutterstock_1569359980_Sundry Photography

18 May 2023Big PharmaMuireann Bolger

US govt seeks new trial in Gilead HIV drug patent case

The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More on this story

Gilead and Teva prevail in $3.6bn antitrust trial

4 July 2023 Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent